Citations (9)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
André J. Scheen. (2017) Dapagliflozin and saxagliptin tablets for adults with type 2 diabetes. Expert Review of Clinical Pharmacology 10:12, pages 1303-1316.
Read now
Read now
Articles from other publishers (8)
Jin-Woo Park, Jong-Min Kim, Ji Hyeon Noh, Kyoung-Ah Kim, Hyewon Chung, EunJi Kim, Minja Kang & Ji-Young Park. (2022) Pharmacokinetics of a Fixed-Dose Combination Product of Dapagliflozin and Linagliptin and Its Comparison with Co-Administration of Individual Tablets in Healthy Humans. Pharmaceutics 14:3, pages 591.
Crossref
Crossref
Juan P. Frías, Jill Maaske, Lisa Suchower, Lars Johansson, Paul D. Hockings, Nayyar Iqbal & John P. H. Wilding. (2021)
Long‐term effects of dapagliflozin plus saxagliptin versus glimepiride on a background of metformin in patients with type 2 diabetes: Results of a 104‐week extension to a 52‐week randomized, phase 3 study and liver fat
MRI
substudy
. Diabetes, Obesity and Metabolism 24:1, pages 61-71.
Crossref
Crossref
Bonpei Takase & Yuko Higashimura. (2021) Effect of Luseogliflozin on liver function, BNP and baPWV in diabetics with coronary artery disease. Vascular Failure 4:2, pages 68-75.
Crossref
Crossref
Lars Johansson, Paul D. Hockings, Eva Johnsson, Nalina Dronamraju, Jill Maaske, Ricardo Garcia‐Sanchez & John P. H. Wilding. (2020) Dapagliflozin plus saxagliptin add‐on to metformin reduces liver fat and adipose tissue volume in patients with type 2 diabetes. Diabetes, Obesity and Metabolism 22:7, pages 1094-1101.
Crossref
Crossref
Tina Vilsbøll, Ella Ekholm, Eva Johnsson, Ricardo Garcia‐Sanchez, Nalina Dronamraju, Serge A. Jabbour & Marcus Lind. (2020) Efficacy and safety of dapagliflozin plus saxagliptin versus insulin glargine over 52 weeks as add‐on to metformin with or without sulphonylurea in patients with type 2 diabetes: A randomized, parallel‐design, open‐label, Phase 3 trial. Diabetes, Obesity and Metabolism 22:6, pages 957-968.
Crossref
Crossref
Andreea-Daniela Meca, Liliana Mititelu Tarțău, Eliza Grațiela Popa, Carmen Gafițanu, Andreea Crețeanu & Maria Bogdan. (2019) New perspectives on oral antidiabetics therapy. Farmacist.ro 187 (2):1, pages 25-28.
Crossref
Crossref
Sanjay Kalra, Sarita Bajaj, AG Unnikrishnan, ManashP Baruah, Rakesh Sahay, V Hardik & Amit Kumar. (2019) Therapeutic experience of saxagliptin as first add-on after metformin in Indian type 2 diabetes patients: A non-interventional, prospective, observational study (ONTARGET-INDIA). Indian Journal of Endocrinology and Metabolism 23:3, pages 312.
Crossref
Crossref
Bonpei Takase, Yuko Higashimura & Kenichi Hashimoto. (2018) Effect of Canagliflozin on endothelial function in diabetic patients with suspected coronary artery disease: retrospective preliminary pilot study. Vascular Failure 2:1, pages 32-38.
Crossref
Crossref